Incretin-based therapy of metabolic disease
Research output: Contribution to journal › Journal article › Research › peer-review
Recent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment. Furthermore, the risk of dementia and cognitive impairment is reduced. A monomolecular coagonist (tirzepatide) of receptors for both incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) produced HbA1c values below 5.7% in 50% of the treated patients and weight losses exceeding 20% in obese individuals. These new agents will radically change our approach to the treatment of T2DM and obesity alike.
Original language | English |
---|---|
Article number | A10220597 |
Journal | Danish Medical Journal |
Volume | 70 |
Issue number | 1 |
ISSN | 2245-1919 |
Publication status | Published - 2023 |
Bibliographical note
Publisher Copyright:
© 2023, Almindelige Danske Laegeforening. All rights reserved.
Links
- https://ugeskriftet.dk/dmj/incretin-based-therapy-metabolic-disease
Final published version
ID: 340118796